CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.51
+0.07 (+1.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.44
Open6.43
Bid0.00 x 800
Ask7.70 x 800
Day's Range6.32 - 6.79
52 Week Range1.20 - 8.29
Volume369,031
Avg. Volume272,996
Market Cap206.809M
Beta (3Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire19 days ago

    Chiasma Set to Join Russell 3000® Index

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the company has been selected for inclusion in the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • GlobeNewswire19 days ago

    Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials

    In the Phase 3 CHIASMA OPTIMAL trial, which is being conducted under a special protocol assessment agreement, or SPA, with FDA, the company announced that the last enrolled patient completed the trial earlier this month. The company now expects to release top-line data by mid-Q3.  Importantly, all 56 patients enrolled in the trial reached the final 36-week visit with no patient dropouts from the trial reported through the 36-week double-blind and controlled phase of the trial.

  • GlobeNewswirelast month

    Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a management transition intended to further strengthen the Company’s leadership team ahead of the anticipated commercial availability of Mycapssa®. As part of the transition, the Company has appointed pharmaceutical commercial veteran Raj Kannan as Chief Executive Officer.  The Company’s current Chief Executive Officer, Mark Fitzpatrick, will continue to serve as President.

  • GlobeNewswire2 months ago

    Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement

    Chiasma recently completed enrollment of its CHIASMA OPTIMAL Phase 3 clinical trial of octreotide capsules, the first potential oral somatostatin analog for the maintenance.

  • GlobeNewswire2 months ago

    Chiasma Reports First Quarter 2019 Results

    During the first quarter of 2019, Chiasma continued to advance its international Phase 3 clinical trial, referred to as CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers), which, if positive, could support potential regulatory approval in the United States of its investigational octreotide capsules, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly. Chiasma anticipates the release of top-line data from this trial during the third quarter of 2019, with an NDA resubmission planned by year-end 2019.

  • GlobeNewswire3 months ago

    Chiasma to Report First Quarter Financial Results on May 9, 2019

    WALTHAM, Mass., April 30, 2019 -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • GlobeNewswire3 months ago

    Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has closed its previously announced underwritten public offering of 7,263,158 shares of its common stock at a price to the public of $4.75 per share for gross proceeds of approximately $34.5 million. Chiasma anticipates using the proceeds from the offering primarily for development costs, including the conduct of its ongoing Phase 3 clinical trials of octreotide capsules, preparation for potential commercialization in the United States, and for working capital and other general corporate purposes. H.C. Wainwright & Co., Roth Capital Partners, Brookline Capital Markets, a division of CIM Securities, LLC and LifeSci Capital LLC acted as co-managers for the offering.

  • GlobeNewswire4 months ago

    Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of an underwritten public offering of 6,315,790 shares of its common stock at a price to the public of $4.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to an additional 947,368 shares of its common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire4 months ago

    Chiasma Announces Proposed Offering of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has commenced an underwritten public offering of its common stock. In addition, Chiasma expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire4 months ago

    Chiasma Announces Three Poster Presentations at ENDO 2019

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced three poster presentations at ENDO 2019: The Endocrine Society’s Annual Meeting and Expo, which is being held March 23-26 in New Orleans. William Ludlam, MD, PhD, Senior Vice President of Clinical Development and Medical Affairs, said, “We are pleased to present three posters at ENDO this year to further educate the endocrinology community on the ongoing challenges associated with the maintenance treatment of adults suffering from acromegaly. Mark Fitzpatrick, Chief Executive Officer of Chiasma, commented, “Our octreotide capsules product candidate, which we have conditionally trade named MYCAPSSA®, is currently being evaluated in two Phase 3 clinical trials and, if approved, could represent a new treatment paradigm by being the first orally-administered somatostatin analog.

  • GlobeNewswire4 months ago

    Chiasma Reports Fourth Quarter and Year End 2018 Results

    On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data,.

  • GlobeNewswire4 months ago

    Chiasma to Participate in Three Investor Conferences in March

    WALTHAM, Mass., March 04, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • GlobeNewswire5 months ago

    Chiasma Announces Support for Rare Disease Day 2019

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced its support for the patient and research communities in recognition of Rare Disease Day 2019. “The theme of Rare Disease Day 2019, ‘Bridging health and social care,’ strikes at the heart of what we are working towards here at Chiasma to improve the lives of people afflicted with acromegaly,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • GlobeNewswire6 months ago

    Chiasma Previews Important Upcoming Milestones

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today previewed anticipated upcoming corporate milestones and commented on the significant progress made by the company in 2018. “During 2018, we completed the required enrollment in both of our Phase 3 clinical trials of our investigational octreotide capsules product candidate, which we have conditionally trade-named Mycapssa®, and with those trials progressing as planned, we believe we have set the stage for a catalyst-rich 2019 including the announcement of topline data evaluating Mycapssa’s efficacy as potentially the first oral somatostatin analog for the maintenance therapy of adult acromegaly patients,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • GlobeNewswire8 months ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    Chiasma Reports Third Quarter 2018 Results

    Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient.

  • GlobeNewswire8 months ago

    Chiasma Supports Acromegaly Awareness Day

    Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. “Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thought leaders who have been instrumental in our efforts to develop an oral treatment alternative for this rare but serious disease,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.